Zug, Switzerland
BE PHARMACEUTICALS AG recalls
2 recalls recorded since 2018, most recently on 10 January 2024. None are listed as ongoing. Status and classification are as published by the FDA.
Recalls2
Ongoing (FDA)0
Terminated or completed2
Class I (FDA)0
Terminated Class II Drugs
- Recall started
- 10 January 2024
- Terminated
- 10 June 2025
- Reason
- Lack of Sterility Assurance: Aseptic process simulation failure.
- Distribution
- Nationwide in the USA
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0262-2024
- Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution and dilution, Single Dose Vial, Rx Only, Distributed by BE Pharmaceuticals Inc. 203 New Edition Court
Terminated Class II Drugs
- Recall started
- 5 September 2023
- Terminated
- 8 April 2025
- Reason
- Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials.
- Distribution
- Nationwide in the USA
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-1148-2023
- Pantoprazole Sodium for Injection 40mg per vial, Single dose vials NDC 71839-122-01 Packaged as (a) 10 Single-dose vials, NDC 71839-122-10; (b) 25 Single-dose vials, NDC 71839-122-25; Rx Only, Mfd. in India for and Distr
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.